Skip to main content
. 2023 Sep 27;30(10):8815–8825. doi: 10.3390/curroncol30100636

Table 2.

STAMPEDE risk classification.

Variables
STAMPEDE
Risk = 0 58 (8.7%)
Risk = 1 432 (64.5%)
Risk = 2 142 (21.2%)
Risk = 3 38 (5.6%)
STAMPEDE risk factors
PSA level ≥ 40 ng/mL 78 (11.6%)
cT stage ≥ 3 300 (44.8%)
Gleason score ≥ 8 452 (67.5%)

PSA: prostate-specific antigen, STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate cancer.